PMGC Holdings (ELAB) Non-Current Assets (2022 - 2026)
PMGC Holdings' (ELAB) quarterly Non-Current Assets came in at $15.7 million in Q2 2026, up 659.01% year-over-year from $2.1 million in Q2 2025, and up 63.08% quarter-over-quarter from $9.6 million in Q1 2026.
Analysis
PMGC Holdings (ELAB) Non-Current Assets (2022 - 2026) Analysis & Trends
PMGC Holdings has disclosed Non-Current Assets across 5 years of filings, most recently posting $15.7 million for Q2 2026.
- In Q2 2026, Non-Current Assets rose 659.01% year-over-year to $15.7 million; the TTM figure through Jun 2026 stood at $15.7 million (up 54.66% YoY), while the FY2025 annual figure was $6.0 million, up 103.84% from the prior year.
- Non-Current Assets came in at $15.7 million for Q2 2026 at PMGC Holdings, up from $9.6 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $306.4 million in Q3 2023 to a low of $270474.0 in Q4 2023.
- Average Non-Current Assets over 5 years is $27.5 million, with a median of $3.0 million recorded in 2024.
- The largest YoY upside for Non-Current Assets was 987.78% in 2024 against a maximum downside of 99.03% in 2024.
- Over 5 years, Non-Current Assets stood at $340861.0 in 2022, then slipped by 20.65% to $270474.0 in 2023, then jumped by 987.78% to $2.9 million in 2024, then surged by 103.84% to $6.0 million in 2025, then jumped by 162.31% to $15.7 million in 2026.
- Per Business Quant data, the three most recent Non-Current Assets figures were $15.7 million in Q2 2026, $9.6 million in Q1 2026, and $6.0 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.09 Bn | 192.10 Bn | 7.24 Bn | 60.68 Bn |
| 2 | Gilead Sciences | 179.75 Bn | 176.57 Bn | 6.22 Bn | 35.42 Bn |
| 3 | Vertex Pharmaceuticals | 131.11 Bn | 123.26 Bn | 2.84 Bn | 14.88 Bn |
| 4 | Regeneron Pharmaceuticals | 81.77 Bn | 73.78 Bn | 3.93 Bn | 23.28 Bn |
| 5 | Argenx Se | 60.45 Bn | 55.27 Bn | 1.37 Bn | 1.96 Bn |
| 6 | Moderna | 53.60 Bn | 48.46 Bn | 52.00 Mn | 5.15 Bn |
| 7 | Alnylam Pharmaceuticals | 33.36 Bn | 30.06 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Biogen | 31.72 Bn | 30.44 Bn | 1.96 Bn | 24.78 Bn |
| 9 | Roivant Sciences | 29.09 Bn | 29.09 Bn | 1.16 Mn | 564.41 Mn |
| 10 | PMGC Holdings | 2.29 Mn | -16.50 Mn | 385,691.00 | 15.73 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 15.73 Mn |
| Mar 31, 2026 | 9.65 Mn |
| Dec 31, 2025 | 6.00 Mn |
| Sep 30, 2025 | 5.17 Mn |
| Jun 30, 2025 | 2.07 Mn |
| Mar 31, 2025 | 2.07 Mn |
| Dec 31, 2024 | 2.94 Mn |
| Sep 30, 2024 | 2.98 Mn |
| Jun 30, 2024 | 3.05 Mn |
| Mar 31, 2024 | 1.09 Mn |
| Dec 31, 2023 | 270,474.00 |
| Sep 30, 2023 | 306.39 Mn |
| Dec 31, 2022 | 340,861.00 |